OTC/DTC Infectious Disease Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Consumers now test themselves for infections at home as a matter of routine. This report estimates consumer-initiated infectious disease testing, measured as end-user (retail) spending, at $3,260 million in 2026, growing 7.1% a year to $4,600 million in 2031 and adding $1,340 million. COVID-19 and combination COVID-19/flu self-tests are now included. Respiratory self-tests are $2,396.1 million, or 73.5% of 2026 spending, but every other application grows faster: Sexually Transmitted at 13.0% a year, Urinary Tract at 11.7% and HIV & Hepatitis at 11.1%. Home Molecular is the fastest growing technology at 29.2% a year, online direct-to-consumer sales grow 10.0% a year and telehealth-linked testing 12.8%, while retail pharmacy grows 4.3%. The US is the largest market at $1,361.8 million, and China grows fastest at 9.5% a year.

The past year reset the rules. COVID-19 emergency use authorisations end on 26 December 2026, the FDA moved COVID-19 antigen tests to Class II, and cleared combination home tests from ACON and iHealth. The FDA cleared Visby Medical's at-home flu and COVID-19 PCR test and Aptitude's next-generation Metrix COVID test, Visby's sexual health PCR self-test went on sale through Quest and Labcorp, and OraSure's Colli-Pee home urine kit was cleared while its CT/NG self-test was withdrawn for resubmission. The report profiles 40 companies, from test makers to labs, telehealth services and retailers, with forecasts for 14 countries and regions.

Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information.

Product Code: IDOTC 1126

List of Tables

List of Figures

1. Executive Summary

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2. Research Methodology & Scope

2.1 Scope & Definitions
2.2 Market Segments
2.3 Geographic Coverage
2.4 Overlap with Sister Reports
2.5 Methodology & Sources
2.6 Limitations

3. Introduction to Consumer Infectious Disease Testing

3.1 What are OTC and DTC Tests?
3.2 Self vs. Send
3.3 The Pandemic Legacy: the Home Antigen Habit
3.4 The Consumer Health and Telehealth Model
3.5 The Industry and Its Players

4. The Global Market for OTC/DTC Infectious Disease Diagnostics

4.1 Global Market Overview by Country
4.2 Global Market by Application – Overview
4.3 Global Market by Channel – Overview
4.4 Global Market by Test Technology – Overview
4.5 Global Market by Product – Overview
4.6 Global Market by Payer – Overview

5. Respiratory Self-Testing

5.1 The Largest Application by Far
5.2 COVID-19 and Combination Antigen Tests
5.3 Home Molecular Testing: Failures and a Second Wave
5.4 The End of COVID-19 EUAs and the New Rules
5.5 Pricing, Retail Economics and Seasonality
5.6 Strep Throat and Other Respiratory Tests

6. Sexual Health, HIV & Hepatitis Self-Testing

6.1 A Fast Growing Pair of Applications
6.2 Home STI Collection Kits and Laboratory Services
6.3 True STI Self-Tests: Syphilis, Home PCR and What Comes Next
6.4 HIV Self-Testing
6.5 Hepatitis C and Hepatitis B Self-Testing
6.6 Doxy-PEP, Screening Guidelines and the Outlook

7. Urinary Tract, Vaginal Health & Other Applications

7.1 The Smaller Applications in Context
7.2 Urinary Tract Infection Self-Testing
7.3 Test-and-Treat in Pharmacies
7.4 Vaginal Health Self-Tests
7.5 Other Applications
7.6 Outlook for These Applications

8. Channels: Retail, Online, Home Collection & Telehealth

8.1 How Consumer Tests Reach the Consumer
8.2 Retail Pharmacy & Mass Merchant
8.3 Online Direct-to-Consumer and Home Collection
8.4 Telehealth-Linked Testing
8.5 Employer & Public Programmes
8.6 Who Pays, and Channel Outlook

9. Technology Landscape

9.1 Overview: Four Technologies, One Consumer
9.2 Lateral Flow Tests and Readers
9.3 Home Molecular Testing
9.4 Sample Collection: Swabs, Blood, Urine and Saliva
9.5 Smartphone Apps and AI Reading
9.6 Connectivity and Result Reporting

10. Regulation, Reimbursement & Policy

10.1 US FDA Pathways for Consumer Tests
10.2 The End of COVID Device EUAs and the Class II Antigen Order
10.3 CLIA, Home Collection and Laboratory-Developed Tests
10.4 Reimbursement: Insurers, FSA/HSA and Government
10.5 Europe and the United Kingdom
10.6 WHO Guidance, China and Asia

11. International Markets

11.1 Regional Overview
11.2 Europe: The Pharmacy Channel
11.3 Africa: HIV Self-Testing Under Funding Pressure
11.4 Asia-Pacific: China, Japan, Korea and India
11.5 Latin America

12. Recent Developments

12.1 Recent Developments – Importance and How to Use This Section
12.2 HHS Ends the COVID-19 Declaration Behind Device EUAs; Home-Test EUAs Lapse on 26 December 2026
12.3 FDA Classifies Point-of-Care SARS-CoV-2 Antigen Tests as Class II; OTC 510(k)s Follow
12.4 FDA Clears Visby Medical’s At-Home Flu & COVID-19 PCR Test
12.5 ACON Launches Flowflex Plus 4-in-1 Home Test, Cleared for Children From 6 Months
12.6 Visby Women’s Sexual Health PCR Self-Test Sold Through Quest and Labcorp OnDemand
12.7 OraSure Withdraws Its InteliQuick CT/NG Molecular Self-Test Submission After FDA Feedback
12.8 FDA Clears OraSure’s Colli-Pee•Dx Home Urine Collection Kit for Roche STI Tests
12.9 Aptitude’s Next-Generation Metrix COVID Home Molecular Test Receives 510(k) Clearance
12.10 iHealth Flu A&B/COVID-19/RSV Rapid Home Test Cleared
12.11 Hims & Hers Raises Its 2026 Outlook and Builds Its Own Lab Testing

13. Operations, Manufacturing & Supply Chain

13.1 Two Supply Chains, One Market
13.2 Lateral Flow Manufacturing
13.3 Tariffs and Trade
13.4 Retail Economics, Private Label and Inventory
13.5 Send-In Kits: Collection Devices and Laboratory Capacity
13.6 Operational Outlook

14. Competitive Landscape

14.1 Market Structure
14.2 Leaders by Application and Channel
14.3 Asian and Emerging Players
14.4 Outlook

15. SWOT, Porter's Five Forces & Investment Risk Analysis

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Investment Risk Analysis

16. Strategic Recommendations

16.1 Guidance for Executives, Marketing, Sales and Business Development
16.2 Guidance for Management Consultants and Investment Advisors

17. Market Forecast by Application, 2026–2031

17.1 Respiratory
17.2 Sexually Transmitted
17.3 Urinary Tract
17.4 HIV & Hepatitis
17.5 Vaginal Health
17.6 Other

18. Market Forecast by Channel, 2026–2031

18.1 Retail Pharmacy & Mass Merchant
18.2 Online Direct-to-Consumer
18.3 Home Collection (Lab-Processed)
18.4 Telehealth-Linked
18.5 Employer & Public Programmes

19. Market Forecast by Test Technology, 2026–2031

19.1 Lateral Flow Antigen
19.2 Lateral Flow Antibody
19.3 Home Molecular
19.4 Dipstick & Other

20. Market Forecast by Product, 2026–2031

20.1 Self-Test Kits
20.2 Sample Collection Kits
20.3 Digital Readers & Apps
20.4 Lab Testing Services

21. Market Forecast by Payer, 2026–2031

21.1 Consumer Out-of-Pocket
21.2 Insurer & FSA/HSA
21.3 Government & Employer

22. Company Profiles

22.1 Abbott Laboratories
22.2 Access Bio
22.3 ACON Laboratories
22.4 Amazon (One Medical and Amazon Pharmacy)
22.5 Aptitude Medical Systems
22.6 Ash (Ash Wellness)
22.7 Assure Tech (Azure Biotech)
22.8 Atomo Diagnostics
22.9 Biosynex (Chembio Diagnostics)
22.10 CVS Health
22.11 Diagnostics for the Real World
22.12 Everlywell (Everly Health)
22.13 Getlabs
22.14 Guangzhou Wondfo Biotech
22.15 Hangzhou AllTest Biotech
22.16 Healgen Scientific
22.17 Healthy.io
22.18 Hims & Hers Health
22.19 iHealth Labs
22.20 Labcorp
22.21 LetsGetChecked (Fuze Health)
22.22 myLAB Box
22.23 NOWDiagnostics (First To Know)
22.24 OraSure Technologies
22.25 Preventx
22.26 Quest Diagnostics
22.27 QuidelOrtho
22.28 Randox Health
22.29 Remedy Meds (Thirty Madison and Nurx)
22.30 Ro
22.31 Roche Diagnostics
22.32 SD Biosensor
22.33 SH:24
22.34 Siemens Healthineers
22.35 Simple HealthKit
22.36 Tasso
22.37 Teal Health
22.38 Visby Medical
22.39 Walgreens
22.40 Waters Corporation (formerly BD Diagnostic Solutions)

23. Appendix

23.1 Abbreviations
23.2 Developments Archive
23.3 Report Limitations Restated

Product Code: IDOTC 1126

List of Tables

Table 1 Key Market Indicators (end-user spending, constant 2026 US$)
Table 2 Global Market by Segment, 2026 and 2031 (US$ millions, constant 2026 dollars)
Table 3 Leading OTC/DTC Infectious Disease Tests, October 2026
Table 4 Overlap with Other HSR Reports
Table 5 Self vs. Send: Two Models of Consumer Testing
Table 6 Milestones in Consumer Infectious Disease Testing
Table 7 Global Market by Country
Table 8 Global Market by Application
Table 9 Global Market by Channel
Table 10 Global Market by Test Technology
Table 11 Global Market by Product
Table 12 Global Market by Payer
Table 13 Respiratory and Related Segments, Global, 2026–2031 (US$ millions, constant 2026 dollars)
Table 14 Selected Respiratory Self-Tests in the US
Table 15 Sexual Health, HIV & Hepatitis and Related Segments, Global, 2026–2031 (US$ millions, constant 2026 dollars)
Table 16 Selected Sexual Health, HIV and Hepatitis Home Tests
Table 17 Urinary Tract, Vaginal Health and Other Applications, Global Market 2026 and 2031
Table 18 Pharmacist Test-and-Treat for Uncomplicated UTI, Selected Countries
Table 19 Main Types of Consumer Vaginal Health Tests
Table 20 Global Market by Channel, 2026 and 2031
Table 21 Leading Online and Home Collection Providers
Table 22 Global Market by Payer, 2026 and 2031
Table 23 Global OTC/DTC Infectious Disease Testing Market by Test Technology, 2026 and 2031
Table 24 Selected Home Molecular Tests and Their Status
Table 25 US FDA Routes to Market for OTC and Home-Collection Tests
Table 26 Global OTC/DTC Infectious Disease Testing Market by Payer, 2026 and 2031
Table 27 OTC/DTC Infectious Disease Testing by Region, 2026 and 2031 (sums of country values; may not add exactly because of rounding)
Table 28 Largest National Markets, 2026 and 2031
Table 29 Recent Developments in This Edition, Summary
Table 30 The Two Supply Chains Compared
Table 31 Main Manufacturing Bases for Consumer Infectious Disease Tests
Table 32 Channels and Their Operational Requirements
Table 33 Competitive Structure by Application
Table 34 Tiers of Participants in Consumer Infectious Disease Testing
Table 35 Leading Companies in Sexual Health, HIV and Hepatitis Self-Testing
Table 36 Leading Participants by Channel
Table 37 SWOT Analysis – Strengths and Weaknesses
Table 38 SWOT Analysis – Opportunities and Threats
Table 39 Porter's Five Forces Ratings
Table 40 Investment Risk Matrix
Table 41 Selected Growth Opportunities
Table 42 Respiratory by Country
Table 43 Sexually Transmitted by Country
Table 44 Urinary Tract by Country
Table 45 HIV & Hepatitis by Country
Table 46 Vaginal Health by Country
Table 47 Other by Country
Table 48 Retail Pharmacy & Mass Merchant by Country
Table 49 Online Direct-to-Consumer by Country
Table 50 Home Collection (Lab-Processed) by Country
Table 51 Telehealth-Linked by Country
Table 52 Employer & Public Programmes by Country
Table 53 Lateral Flow Antigen by Country
Table 54 Lateral Flow Antibody by Country
Table 55 Home Molecular by Country
Table 56 Dipstick & Other by Country
Table 57 Self-Test Kits by Country
Table 58 Sample Collection Kits by Country
Table 59 Digital Readers & Apps by Country
Table 60 Lab Testing Services by Country
Table 61 Consumer Out-of-Pocket by Country
Table 62 Insurer & FSA/HSA by Country
Table 63 Government & Employer by Country

List of Figures

Figure 1 Key Graphic – Online Channels Overtake the Pharmacy: OTC/DTC Infectious Disease Diagnostics Market by Channel, 2026 vs 2031
Figure 2 Global Market Pareto Chart
Figure 3 Global Market by Application - Base vs. Final
Figure 4 Global Market by Application Base Year
Figure 5 Global Market by Application End Year
Figure 6 Application Share by Year
Figure 7 Application Segments Growth
Figure 8 Global Market by Channel - Base vs. Final
Figure 9 Global Market by Channel Base Year
Figure 10 Global Market by Channel End Year
Figure 11 Channel Share by Year
Figure 12 Channel Segments Growth
Figure 13 Global Market by Test Technology - Base vs. Final
Figure 14 Global Market by Test Technology Base Year
Figure 15 Global Market by Test Technology End Year
Figure 16 Test Technology Share by Year
Figure 17 Test Technology Segments Growth
Figure 18 Global Market by Product - Base vs. Final
Figure 19 Global Market by Product Base Year
Figure 20 Global Market by Product End Year
Figure 21 Product Share by Year
Figure 22 Product Segments Growth
Figure 23 Global Market by Payer - Base vs. Final
Figure 24 Global Market by Payer Base Year
Figure 25 Global Market by Payer End Year
Figure 26 Payer Share by Year
Figure 27 Payer Segments Growth
Figure 28 Respiratory Growth
Figure 29 Sexually Transmitted Growth
Figure 30 Urinary Tract Growth
Figure 31 HIV & Hepatitis Growth
Figure 32 Vaginal Health Growth
Figure 33 Other Growth
Figure 34 Retail Pharmacy & Mass Merchant Growth
Figure 35 Online Direct-to-Consumer Growth
Figure 36 Home Collection (Lab-Processed) Growth
Figure 37 Telehealth-Linked Growth
Figure 38 Employer & Public Programmes Growth
Figure 39 Lateral Flow Antigen Growth
Figure 40 Lateral Flow Antibody Growth
Figure 41 Home Molecular Growth
Figure 42 Dipstick & Other Growth
Figure 43 Self-Test Kits Growth
Figure 44 Sample Collection Kits Growth
Figure 45 Digital Readers & Apps Growth
Figure 46 Lab Testing Services Growth
Figure 47 Consumer Out-of-Pocket Growth
Figure 48 Insurer & FSA/HSA Growth
Figure 49 Government & Employer Growth

OTC/DTC Infectious Disease Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Description

Table of Contents

List of Tables

Report Overview:

Table of Contents

List of Tables

List of Figures

1. Executive Summary

2. Research Methodology & Scope

3. Introduction to Consumer Infectious Disease Testing

4. The Global Market for OTC/DTC Infectious Disease Diagnostics

5. Respiratory Self-Testing

6. Sexual Health, HIV & Hepatitis Self-Testing

7. Urinary Tract, Vaginal Health & Other Applications

8. Channels: Retail, Online, Home Collection & Telehealth

9. Technology Landscape

10. Regulation, Reimbursement & Policy

11. International Markets

12. Recent Developments

13. Operations, Manufacturing & Supply Chain

14. Competitive Landscape

15. SWOT, Porter's Five Forces & Investment Risk Analysis

16. Strategic Recommendations

17. Market Forecast by Application, 2026–2031

18. Market Forecast by Channel, 2026–2031

19. Market Forecast by Test Technology, 2026–2031

20. Market Forecast by Product, 2026–2031

21. Market Forecast by Payer, 2026–2031

22. Company Profiles

23. Appendix

List of Tables

List of Figures